S&P 500   3,379.84 (+1.33%)
DOW   27,898.90 (+1.63%)
QQQ   279.57 (+1.31%)
AAPL   116.56 (+2.16%)
MSFT   211.74 (+2.16%)
FB   265.64 (+1.47%)
GOOGL   1,478.18 (+0.83%)
AMZN   3,204.89 (+1.91%)
TSLA   430.48 (+2.72%)
NVDA   543.07 (+2.65%)
BABA   291.95 (+5.42%)
CGC   14.69 (+1.31%)
GE   6.23 (+1.80%)
MU   48.15 (-5.05%)
AMD   82.38 (+0.75%)
T   28.42 (+0.42%)
F   6.63 (+0.45%)
ACB   4.79 (+2.35%)
GILD   62.77 (+1.08%)
NFLX   499.58 (+1.24%)
DIS   124.31 (-0.87%)
BA   165.99 (+1.46%)
BAC   24.04 (+1.14%)
S&P 500   3,379.84 (+1.33%)
DOW   27,898.90 (+1.63%)
QQQ   279.57 (+1.31%)
AAPL   116.56 (+2.16%)
MSFT   211.74 (+2.16%)
FB   265.64 (+1.47%)
GOOGL   1,478.18 (+0.83%)
AMZN   3,204.89 (+1.91%)
TSLA   430.48 (+2.72%)
NVDA   543.07 (+2.65%)
BABA   291.95 (+5.42%)
CGC   14.69 (+1.31%)
GE   6.23 (+1.80%)
MU   48.15 (-5.05%)
AMD   82.38 (+0.75%)
T   28.42 (+0.42%)
F   6.63 (+0.45%)
ACB   4.79 (+2.35%)
GILD   62.77 (+1.08%)
NFLX   499.58 (+1.24%)
DIS   124.31 (-0.87%)
BA   165.99 (+1.46%)
BAC   24.04 (+1.14%)
S&P 500   3,379.84 (+1.33%)
DOW   27,898.90 (+1.63%)
QQQ   279.57 (+1.31%)
AAPL   116.56 (+2.16%)
MSFT   211.74 (+2.16%)
FB   265.64 (+1.47%)
GOOGL   1,478.18 (+0.83%)
AMZN   3,204.89 (+1.91%)
TSLA   430.48 (+2.72%)
NVDA   543.07 (+2.65%)
BABA   291.95 (+5.42%)
CGC   14.69 (+1.31%)
GE   6.23 (+1.80%)
MU   48.15 (-5.05%)
AMD   82.38 (+0.75%)
T   28.42 (+0.42%)
F   6.63 (+0.45%)
ACB   4.79 (+2.35%)
GILD   62.77 (+1.08%)
NFLX   499.58 (+1.24%)
DIS   124.31 (-0.87%)
BA   165.99 (+1.46%)
BAC   24.04 (+1.14%)
S&P 500   3,379.84 (+1.33%)
DOW   27,898.90 (+1.63%)
QQQ   279.57 (+1.31%)
AAPL   116.56 (+2.16%)
MSFT   211.74 (+2.16%)
FB   265.64 (+1.47%)
GOOGL   1,478.18 (+0.83%)
AMZN   3,204.89 (+1.91%)
TSLA   430.48 (+2.72%)
NVDA   543.07 (+2.65%)
BABA   291.95 (+5.42%)
CGC   14.69 (+1.31%)
GE   6.23 (+1.80%)
MU   48.15 (-5.05%)
AMD   82.38 (+0.75%)
T   28.42 (+0.42%)
F   6.63 (+0.45%)
ACB   4.79 (+2.35%)
GILD   62.77 (+1.08%)
NFLX   499.58 (+1.24%)
DIS   124.31 (-0.87%)
BA   165.99 (+1.46%)
BAC   24.04 (+1.14%)
Log in
NASDAQ:STOK

Stoke Therapeutics Stock Forecast, Price & News

$33.87
-0.46 (-1.34 %)
(As of 09/30/2020 11:46 AM ET)
Add
Compare
Today's Range
$33.38
Now: $33.87
$34.00
50-Day Range
$27.97
MA: $30.85
$37.48
52-Week Range
$15.82
Now: $33.87
$37.88
Volume1,169 shs
Average Volume159,151 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.36
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STOK
CUSIPN/A
CIKN/A
Phone781-430-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.86 per share

Profitability

Net Income$-32,330,000.00

Miscellaneous

Employees44
Market Cap$1.13 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$33.87
-0.46 (-1.34 %)
(As of 09/30/2020 11:46 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

How has Stoke Therapeutics' stock been impacted by Coronavirus?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STOK stock has increased by 71.7% and is now trading at $33.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Stoke Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Stoke Therapeutics
.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Stoke Therapeutics
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04.
View Stoke Therapeutics' earnings history
.

What price target have analysts set for STOK?

7 brokerages have issued twelve-month price targets for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $46.00. On average, they anticipate Stoke Therapeutics' stock price to reach $37.67 in the next twelve months. This suggests a possible upside of 11.2% from the stock's current price.
View analysts' price targets for Stoke Therapeutics
.

Who are some of Stoke Therapeutics' key competitors?

What other stocks do shareholders of Stoke Therapeutics own?

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:
  • Dr. Edward M. Kaye, CEO & Director (Age 70)
  • Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
  • Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
  • Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $33.87.

How big of a company is Stoke Therapeutics?

Stoke Therapeutics has a market capitalization of $1.13 billion. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.